Denifanstat Sustains Acne Improvement Through 52 Weeks in Phase 3 Extension Study

Oral denifanstat, a once-daily fatty acid synthase (FASN) inhibitor under development for moderate to severe acne vulgaris, demonstrated sustained efficacy through 52 weeks in a Phase 3 open-label...
Read the full report on Business Medical Dialogues
Story file
- Section
- Health
- First reported by
- Business Medical Dialogues
- Reporter
- dr. kamal kant kohli
- Published
- Monday, 12 October 2026, 9:15 pm IST
- Coverage
- One outlet so far
How this page works. The Headline Update lists this report from Business Medical Dialogues with a short summary and a link to the original. The original reporting and photograph belong to the publisher. Spotted an error in our summary? Tell our corrections desk.